Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404
Help Center
Careers
Contact

Immune-Mediated Inflammatory Diseases (IMID) Treatment Market

Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, Share & Trends Analysis Report, By Drug Class (Biologics, Targeted Synthetic DMARDs, Conventional DMARDs, Corticosteroids, NSAIDs), By Disease Type (Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Inflammatory Bowel Disease (IBD), Ankylosing Spondylitis (AS), Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS), Others), By Treatment Type (Targeted Biologic Therapies, Novel Therapies), Forecast Period (2026–2035)

Published: May 2026 | Report Code: OMR2029472 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Immune-mediated inflammatory diseases treatment market was valued at $121.0 billion in 2025 and is projected to reach $191.04 billion by 2035, expanding at a CAGR of 4.67% during 2026–2035. The market growth is primarily driven by the increasing global burden of autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.

According to the Global Autoimmune Institute, autoimmune diseases affect nearly 5–10% of the global population, highlighting a substantial and growing patient pool. Additionally, data from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) indicates that biologics and targeted therapies account for a significant portion of innovation in immunology treatment pipelines.

Pharmaceutical companies are increasingly investing in biologics and targeted synthetic DMARDs (tsDMARDs) to improve treatment outcomes and reduce disease progression. Major end-use sectors include hospitals, specialty clinics, and home care settings. Rising healthcare expenditure, particularly in emerging economies, and regulatory approvals from agencies such as the U.S. Food and Drug Administration (FDA) are further accelerating market expansion.

Market Dynamics

Rising Prevalence of Autoimmune Diseases Driving Market Growth

The increasing incidence of immune-mediated inflammatory diseases is a major driver of the IMID treatment market. According to the WHO, chronic diseases, including autoimmune disorders, account for over 70% of global deaths, indicating a rising need for long-term therapeutic solutions. Furthermore, the OECD reports a steady increase in healthcare expenditure, particularly in developed economies, supporting access to advanced biologic therapies.

The demand for targeted biologics and precision medicine is growing rapidly, with pharmaceutical companies focusing on monoclonal antibodies and interleukin inhibitors. Between 2024 and 2026, leading players such as AbbVie and Novartis expanded their immunology portfolios through product launches and pipeline advancements. Additionally, the FDA continues to approve innovative therapies, accelerating patient access to advanced treatment options.

High Cost of Biologics and Regulatory Complexities Restraining Market Growth

Despite strong growth potential, the IMID treatment market faces significant challenges due to the high cost of biologic therapies. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), biologics can cost significantly more than conventional therapies, limiting accessibility in low- and middle-income countries.

Supply chain complexities and stringent regulatory requirements further hinder market growth. The development and approval of biologics require extensive clinical trials and compliance with regulatory standards set by authorities such as the FDA and the European Commission. Additionally, biosimilar competition is putting pricing pressure on original biologics, affecting revenue margins. To address these challenges, companies are investing in cost-effective biosimilars and localized manufacturing capabilities. Strategic collaborations and partnerships are also being pursued to enhance global distribution and reduce costs.

Market Segmentation

  • Based on the drug class, the market is segmented into biologics, targeted synthetic DMARDs (tsDMARDs), conventional DMARDs (csDMARDs), corticosteroids, and NSAIDs.
  • Based on the disease type, the market is segmented into rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA), inflammatory bowel disease (IBD), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), multiple sclerosis (MS), and others.
  • Based on the treatment type, the market is segmented into targeted biologic therapies and novel therapies.

Biologics Segment Leads the Market

The biologics segment dominates the IMID treatment market due to its superior efficacy in targeting specific immune pathways. Biologics, including TNF inhibitors and interleukin inhibitors, are widely used in treating chronic conditions such as rheumatoid arthritis and psoriasis.

The increasing adoption of biologics is supported by clinical evidence demonstrating improved patient outcomes and reduced disease progression. Between 2022 and 2026, pharmaceutical companies significantly expanded their biologics portfolios, with increased investment in monoclonal antibody therapies. Additionally, regulatory approvals from the FDA and the European Commission have facilitated market penetration.

Targeted Synthetic DMARDs (tsDMARDs) Segment to Record Strong Growth

Targeted synthetic DMARDs, particularly JAK inhibitors, are expected to witness the fastest growth during the forecast period. These therapies offer oral administration and improved convenience compared to injectable biologics.

Technological advancements and ongoing clinical trials are driving innovation in this segment. Increased investment in research and development, along with favorable regulatory approvals, is accelerating market adoption. Emerging applications in multiple autoimmune diseases further enhance growth prospects.

Regional Outlook

The global Immune-Mediated Inflammatory Diseases (IMID) Treatment market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the IMID treatment market due to advanced healthcare infrastructure and high adoption of biologic therapies. According to the U.S. Food and Drug Administration (FDA), the country accounts for a significant share of global biologic drug approvals. Additionally, the Pharmaceutical Research and Manufacturers of America (PhRMA) highlights substantial R&D investments in immunology, supporting innovation and market growth.

China to Record Strong Growth

China is expected to witness significant growth due to expanding healthcare infrastructure and increasing prevalence of autoimmune diseases. Data from the OECD and WHO indicate rising healthcare expenditure and improved access to advanced treatments. Additionally, government initiatives to promote domestic pharmaceutical manufacturing are driving market expansion.

Market Player Outlook  

The IMID treatment market is highly competitive, characterized by the presence of global pharmaceutical giants and emerging biotech firms. Companies are focusing on innovation, product differentiation, and strategic collaborations to strengthen their market position. Leading players such as AbbVie Inc., Johnson & Johnson, Sanofi S.A., Novartis AG, and Roche (Genentech) dominate the market through strong biologics portfolios and extensive R&D investments. These companies are actively engaged in developing next-generation therapies and expanding their global footprint.

Recent Developments

  • In October 2025, Bristol Myers Squibb strengthened its position in the Immune-Mediated Inflammatory Diseases (IMID) market through the acquisition of Orbital Therapeutics, enhancing its cell therapy and RNA-based innovation capabilities. The deal includes OTX-201, a next-generation in vivo CAR T-cell therapy targeting autoimmune diseases, designed to improve accessibility and reduce treatment complexity.
  • In June 2024, AstraZeneca reinforced its strategic focus in the Immune-Mediated Inflammatory Diseases (IMID) market by advancing research aimed at achieving disease remission rather than mere symptom control. The company is leveraging deep immunology expertise to develop innovative therapies targeting underlying immune pathways across conditions like lupus and inflammatory bowel disease.

The Report Covers

  • Market value data analysis of 2025 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global Immune-Mediated Inflammatory Diseases (IMID) Treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.

 

  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Sales Analysis – Drug Class | Disease Type | Treatment Type ($ Million)
  • Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Sales Performance of Top Countries

1.1 Research Methodology

  • Primary Research Approach
  • Secondary Research Approach

1.2 Market Snapshot

  1. Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

 2.2.1 Key Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Trends

 2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Immune-Mediated Inflammatory Diseases (IMID) Treatment Market

 2.3.1 Competitive Rivalry

 2.3.2 Threat of New Entrants

 2.3.3 Bargaining Power of Suppliers

 2.3.4 Bargaining Power of Buyers

 2.3.5 Threat of Substitutes

  1. Market Determinants

3.1 Market Drivers

 3.1.1 Drivers For Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market: Impact Analysis

3.2 Market Pain Points and Challenges

 3.2.1 Restraints For Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market: Impact Analysis

3.3 Market Opportunities

 3.3.1 Opportunities For Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market: Impact Analysis

  1. Competitive Landscape

4.1 Competitive Dashboard – Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Revenue and Share by Manufacturers

  • Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Comparison Analysis
  • Top Market Player Ranking Matrix

4.2 Key Company Analysis

 4.2.1 AbbVie Inc.

 4.2.1.1 Overview

 4.2.1.2 Product Portfolio

 4.2.1.3 Financial Analysis

 4.2.1.4 SWOT Analysis

 4.2.1.5 Business Strategy

 4.2.2 Johnson & Johnson

 4.2.2.1 Overview

 4.2.2.2 Product Portfolio

 4.2.2.3 Financial Analysis

 4.2.2.4 SWOT Analysis

 4.2.2.5 Business Strategy

 4.2.3 Sanofi S.A.

 4.2.3.1 Overview

 4.2.3.2 Product Portfolio

 4.2.3.3 Financial Analysis

 4.2.3.4 SWOT Analysis

 4.2.3.5 Business Strategy

 4.2.4 Novartis AG

 4.2.4.1 Overview

 4.2.4.2 Product Portfolio

 4.2.4.3 Financial Analysis

 4.2.4.4 SWOT Analysis

 4.2.4.5 Business Strategy

 4.2.5 Roche Holding AG (Genentech)

 4.2.5.1 Overview

 4.2.5.2 Product Portfolio

 4.2.5.3 Financial Analysis

 4.2.5.4 SWOT Analysis

 4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

 4.3.1 Merger and Acquisition

 4.3.2 Product Launch

 4.3.3 Partnership And Collaboration

  1. Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Sales Analysis by Drug Class ($ Million)

5.1 Biologics

5.2 Targeted Synthetic DMARDs (tsDMARDs)

5.3 Conventional DMARDs (csDMARDs)

5.4 Corticosteroids

5.5 NSAIDs

  1. Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Sales Analysis by Disease Type ($ Million)

6.1 Rheumatoid Arthritis (RA)

6.2 Psoriasis

6.3 Psoriatic Arthritis (PsA)

6.4 Inflammatory Bowel Disease (IBD)

6.5 Ankylosing Spondylitis (AS)

6.6 Systemic Lupus Erythematosus (SLE)

6.7 Multiple Sclerosis (MS)

6.8 Others

  1. Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Sales Analysis by Treatment Type ($ Million)

7.1 Targeted Biologic Therapies

7.2 Novel Therapies

  1. Regional Analysis

8.1 North American Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Sales Analysis – Drug Class | Disease Type | Treatment Type | Country ($ Million)

 8.1.1 United States

 8.1.2 Canada

8.2 European Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Sales Analysis – Drug Class | Disease Type | Treatment Type | Country ($ Million)

 8.2.1 UK

 8.2.2 Germany

 8.2.3 Italy

 8.2.4 Spain

 8.2.5 France

 8.2.6 Russia

 8.2.7 Rest of Europe

8.3 Asia-Pacific Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Sales Analysis – Drug Class | Disease Type | Treatment Type | Country ($ Million)

 8.3.1 China

 8.3.2 Japan

 8.3.3 South Korea

 8.3.4 India

 8.3.5 Australia & New Zealand

 8.3.6 ASEAN Countries

 8.3.7 Rest of Asia-Pacific

8.4 Rest of the World Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Sales Analysis – Drug Class | Disease Type | Treatment Type | Country ($ Million)

 8.4.1 Latin America

 8.4.2 Middle East and Africa

  1. Company Profiles

9.1 Amgen Inc. (Horizon Therapeutics)

 9.1.1 Quick Facts

 9.1.2 Company Overview

 9.1.3 Product Portfolio

 9.1.4 Business Strategies

9.2 AstraZeneca PLC

 9.2.1 Quick Facts

 9.2.2 Company Overview

 9.2.3 Product Portfolio

 9.2.4 Business Strategies

9.3 Bayer AG

 9.3.1 Quick Facts

 9.3.2 Company Overview

 9.3.3 Product Portfolio

 9.3.4 Business Strategies

9.4 Biogen Inc.

 9.4.1 Quick Facts

 9.4.2 Company Overview

 9.4.3 Product Portfolio

 9.4.4 Business Strategies

9.5 Boehringer Ingelheim

 9.5.1 Quick Facts

 9.5.2 Company Overview

 9.5.3 Product Portfolio

 9.5.4 Business Strategies

9.6 Bristol Myers Squibb (BMS)

 9.6.1 Quick Facts

 9.6.2 Company Overview

 9.6.3 Product Portfolio

 9.6.4 Business Strategies

9.7 Eli Lilly and Company

 9.7.1 Quick Facts

 9.7.2 Company Overview

 9.7.3 Product Portfolio

 9.7.4 Business Strategies

9.8 Galderma S.A.

 9.8.1 Quick Facts

 9.8.2 Company Overview

 9.8.3 Product Portfolio

 9.8.4 Business Strategies

9.9 Gilead Sciences, Inc.

 9.9.1 Quick Facts

 9.9.2 Company Overview

 9.9.3 Product Portfolio

 9.9.4 Business Strategies

9.10 GlaxoSmithKline (GSK)

 9.10.1 Quick Facts

 9.10.2 Company Overview

 9.10.3 Product Portfolio

 9.10.4 Business Strategies

9.11 Incyte Corporation

 9.11.1 Quick Facts

 9.11.2 Company Overview

 9.11.3 Product Portfolio

 9.11.4 Business Strategies

9.12 LEO Pharma A/S

 9.12.1 Quick Facts

 9.12.2 Company Overview

 9.12.3 Product Portfolio

 9.12.4 Business Strategies

9.13 Merck & Co. (MSD)

 9.13.1 Quick Facts

 9.13.2 Company Overview

 9.13.3 Product Portfolio

 9.13.4 Business Strategies

9.14 Organon & Co.

 9.14.1 Quick Facts

 9.14.2 Company Overview

 9.14.3 Product Portfolio

 9.14.4 Business Strategies

9.15 Pfizer Inc.

 9.15.1 Quick Facts

 9.15.2 Company Overview

 9.15.3 Product Portfolio

 9.15.4 Business Strategies

9.16 Regeneron Pharmaceuticals

 9.16.1 Quick Facts

 9.16.2 Company Overview

 9.16.3 Product Portfolio

 9.16.4 Business Strategies

9.17 Sandoz Group AG

 9.17.1 Quick Facts

 9.17.2 Company Overview

 9.17.3 Product Portfolio

 9.17.4 Business Strategies

9.18 Takeda Pharmaceutical Co.

 9.18.1 Quick Facts

 9.18.2 Company Overview

 9.18.3 Product Portfolio

 9.18.4 Business Strategies

9.19 UCB S.A.

 9.19.1 Quick Facts

 9.19.2 Company Overview

 9.19.3 Product Portfolio

 9.19.4 Business Strategies

9.20 Viatris Inc.

 9.20.1 Quick Facts

 9.20.2 Company Overview

 9.20.3 Product Portfolio

 9.20.4 Business Strategies

1. Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

2. Global Biologics Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

3. Global Targeted Synthetic DMARDs (tsDMARDs) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

4. Global Conventional DMARDs (csDMARDs) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

5. Global Corticosteroids Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

6. Global NSAIDs Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

7. Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Disease Type, 2025–2035 ($ Million)

8. Global Rheumatoid Arthritis (RA) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

9. Global Psoriasis Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

10. Global Psoriatic Arthritis (PsA) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

11. Global Inflammatory Bowel Disease (IBD) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

12. Global Ankylosing Spondylitis (AS) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

13. Global Systemic Lupus Erythematosus (SLE) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

14. Global Multiple Sclerosis (MS) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

15. Global Others Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

16. Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

17. Global Targeted Biologic Therapies Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

18. Global Novel Therapies Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

19. Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

20. North America Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)

21. North America Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

22. North America Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Disease Type, 2025–2035 ($ Million)

23. North America Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

24. Europe Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)

25. Europe Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

26. Europe Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Disease Type, 2025–2035 ($ Million)

27. Europe Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

28. Asia-Pacific Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)

29. Asia-Pacific Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

30. Asia-Pacific Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Disease Type, 2025–2035 ($ Million)

31. Asia-Pacific Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

32. Rest of the World Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

33. Rest of the World Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

34. Rest of the World Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Disease Type, 2025–2035 ($ Million)

35. Rest of the World Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

1. Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Share by Drug Class, 2025 Vs 2035 (%)

2. Global Biologics Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

3. Global Targeted Synthetic DMARDs (tsDMARDs) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

4. Global Conventional DMARDs (csDMARDs) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

5. Global Corticosteroids Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

6. Global NSAIDs Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

7. Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Share by Disease Type, 2025 Vs 2035 (%)

8. Global Rheumatoid Arthritis (RA) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

9. Global Psoriasis Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

10. Global Psoriatic Arthritis (PsA) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

11. Global Inflammatory Bowel Disease (IBD) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

12. Global Ankylosing Spondylitis (AS) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

13. Global Systemic Lupus Erythematosus (SLE) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

14. Global Multiple Sclerosis (MS) Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

15. Global Others Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

16. Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Share by Treatment Type, 2025 Vs 2035 (%)

17. Global Immune-Mediated Inflammatory Diseases (IMID) Treatment for Targeted Biologic Therapies Market Research and Analysis by Region, 2025 Vs 2035 (%)

18. Global Immune-Mediated Inflammatory Diseases (IMID) Treatment for Novel Therapies Market Research and Analysis by Region, 2025 Vs 2035 (%)

19. Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Share by Region, 2025 Vs 2035 (%)

20. United States Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

21. Canada Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

22. UK Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

23. France Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

24. Germany Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

25. Italy Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

26. Spain Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

27. Russia Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

28. India Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

29. China Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

30. Japan Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

31. South Korea Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

32. Australia & New Zealand Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

33. ASEAN Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

34. Rest of Asia-Pacific Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

35. Latin America Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

36. Middle East & Africa Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, 2025-2035 ($ Million)

Choose License Type
    On Discount
Enterprise Custom
  • Printable version
  • No restriction to number of users within the company
CONTACT SALES

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The IMID treatment market was valued at $121.0 billion in 2025 and is projected to reach $191.04 billion by 2035.
The market is expected to grow at a CAGR of 4.67% during the forecast period 2026–2035.
The biologics segment dominates due to its high efficacy and widespread adoption in treating autoimmune diseases.
North America, particularly the United States, leads the market due to advanced healthcare infrastructure and high biologics adoption.
Key trends include increasing adoption of biologics, growth of JAK inhibitors, and rising investment in precision medicine.